search
Back to results

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue (PEI)

Primary Purpose

Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PEI Experimental Light
Comparison Light
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cancer-related Problem/Condition focused on measuring Autologous Stem Cell Transplant, Multiple Myeloma, oncology, circadian rhythms, light therapy, Hematopoietic stem cell transplantation

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Who will undergo their first autologous HSCT procedure as treatment for multiple myeloma

AND:

  • Who are currently 21 years of age or older
  • English language proficient
  • Able to provide informed consent

Exclusion Criteria:

  • Under age 21
  • Previous HSCT procedure (autologous or allogeneic)Pregnancy
  • Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage)
  • Secondary cancer diagnosis within the last 5 years
  • Severe sleep disorders (e.g., Narcolepsy)
  • History of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
  • Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
  • Previous use of light therapy to alleviate fatigue or depressive symptoms

Sites / Locations

  • Icahn School of Medicine at Mount Sinai

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PEI Experimental Light

Comparison Light

Arm Description

Ambient light fixture installed in the patient's hospital room

Ambient light fixture installed in the patient's hospital room

Outcomes

Primary Outcome Measures

FACIT-Fatigue Scale
The FACIT-Fatigue scale is a13 item scale, full scale 0-52, with higher score indicating better functioning or less fatigue.

Secondary Outcome Measures

Multidimensional Fatigue
The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Tested for its psychometric properties in cancer patients receiving radiotherapy, patients with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians, it was found to have good Test-retest Reliability (r=0.80) and great Internal Consistency (Cronbach's alpha = 0.92).
The Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index consists of 19 self-rated instrument full scale from 0-21, with higher score indicating poorer sleep quality.
SF-36 Scale
Quality of life assessed using the SF-36 scale. The SF-36 is a multi-purpose, short form health survey consisting of 36 questions. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability
Number of Participants With Score 16 or Greater on CES-D (Center for Epidemiologic Studies Depression Scale)
Number of participants with score 16 or greater on CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
CES-D (Center for Epidemiologic Studies Depression Scale)
CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
The Positive and Negative Affect Schedule (PANAS)
PANAS is a 20-item self-report measure of positive and negative affect. Each item rated on a 5-point scale of 1 (not at all) to 5 (extremely), each subscale from 1-5, full score from 1-5, with higher score indicating more symptoms. Change in PANAS at Day 30 and Day 90 as compared to baseline.
Change in Brief Symptoms Inventory-18 (BSI-18)
Brief Symptom Inventory-18 (BSI-18) - self-report 18-item instrument. Raw scores on the BSI-18 are converted to t-scores based on gender-specific normative data from non-patient community dwelling U.S. adults. A T-score = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating more symptom.
Fatigue Line Scale
Simple numeric graphic rating scale, marked on a line numbering 0-100, with higher score indicating more fatigue. Replaces the FACIT fatigue scale for daily fatigue assessment during inpatient procedures.
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF)
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF) is a 30-item short form of the MFSI that measures five dimensions: general, physical, emotional, mental fatigue, and vigor. Each item is rated on a five-point Likert scale from 0 (not at all) to 4 (extremely). The total MFSI-SF score ranges from 0-4, with a higher score indicating a higher fatigue level.
Sleep Latency
Sleep latency measured by actigraph - Sleep latency is the average period of time between bed time and sleep start time
Sleep Efficiency
Sleep efficiency measured by actigraph - Sleep efficiency is defined as the average percentage of time in bed actually spent sleeping
Wake Time
Wake time measured by actigraph. Wake time is the average number of minutes the participant spent awake each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Wake Percent
Wake percent measured by actigraph - Wake percent is the average percent of each night spent awake
Sleep Time
Sleep time measured by actigraph. Sleep time - average number of minutes the participant was asleep each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Sleep Percent
Sleep percent measured by actigraph. Sleep percent is the percent of time spent in bed that the participant is asleep.
Melatonin
Melatonin level

Full Information

First Posted
June 21, 2017
Last Updated
July 27, 2020
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT03198754
Brief Title
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
Acronym
PEI
Official Title
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue During Hematopoetic Stem Cell Transplantation for Multiple Myeloma
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
July 22, 2016 (Actual)
Primary Completion Date
January 23, 2019 (Actual)
Study Completion Date
January 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization. Light therapy incorporating ambient Programmed Environmental Illumination (PEI) will be used in patient hospital rooms (during scheduled transplant) to control cancer-related fatigue (CRF). The FDA has certified that light therapy, like that used in this study, is a low-risk intervention. When admitted to the hospital for a stem cell transplant, there will be a light fixture in the hospital room which the researchers will be testing to see how it may affect cancer related fatigue, sleep quality, and other negative side effects often seen with the transplant and subsequent treatment. The light fixture will turn on and off by itself in the morning. There are two treatment arms used in the study, each of the arms uses different light intensities. The study treatment received, i.e. which of the two lights, will be chosen by chance, like flipping a coin. There is an equal chance of being given each study treatment. Participants will not be told which study treatment they are getting until after the study is completed. Each light will be turned on from 7 AM to 10AM every day during transplantation. While in the hospital, assessment of fatigue, sleep activity, depression, circadian rhythms, and quality of life will continue through the course of hospitalization (14-21 days of treatment, to determine immediate impact of sPI), then repeat at one month and three months post-discharge follow-ups (to determine lasting effects). Outcomes will be assessed through standardized scales (e.g., FACIT-Fatigue Scale) and objective measures (e.g., actigraphy, daysimeter for light monitoring, melatonin from urine collection, blood inflammatory markers, all explained below). This trial will: 1) be the first randomized clinical trial (RCT) to investigate the effects of sPI to prevent CRF and other biopsychosocial side effects of transplant; 2) focus on a distinct, relatively homogenous patient population (MM-HSCT patients) with high prevalence of CRF; and 3) explore possible circadian rhythm mediation via melatonin analysis and blood analysis. This investigation will have major public health relevance as it will determine if an inexpensive and low patient burden intervention (sPI) is able to control fatigue associated with medical illnesses and related problems.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
Keywords
Autologous Stem Cell Transplant, Multiple Myeloma, oncology, circadian rhythms, light therapy, Hematopoietic stem cell transplantation

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Masking Description
Neither the study participant nor the research coordinator know that study condition of the patient.
Allocation
Randomized
Enrollment
73 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PEI Experimental Light
Arm Type
Experimental
Arm Description
Ambient light fixture installed in the patient's hospital room
Arm Title
Comparison Light
Arm Type
Active Comparator
Arm Description
Ambient light fixture installed in the patient's hospital room
Intervention Type
Device
Intervention Name(s)
PEI Experimental Light
Intervention Description
Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Intervention Type
Device
Intervention Name(s)
Comparison Light
Intervention Description
Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Primary Outcome Measure Information:
Title
FACIT-Fatigue Scale
Description
The FACIT-Fatigue scale is a13 item scale, full scale 0-52, with higher score indicating better functioning or less fatigue.
Time Frame
Baseline, Day 2, 7, 14, 28 and 90
Secondary Outcome Measure Information:
Title
Multidimensional Fatigue
Description
The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Tested for its psychometric properties in cancer patients receiving radiotherapy, patients with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians, it was found to have good Test-retest Reliability (r=0.80) and great Internal Consistency (Cronbach's alpha = 0.92).
Time Frame
up to 3 months
Title
The Pittsburgh Sleep Quality Index
Description
The Pittsburgh Sleep Quality Index consists of 19 self-rated instrument full scale from 0-21, with higher score indicating poorer sleep quality.
Time Frame
Baseline, Day 30 and Day 90
Title
SF-36 Scale
Description
Quality of life assessed using the SF-36 scale. The SF-36 is a multi-purpose, short form health survey consisting of 36 questions. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability
Time Frame
Baseline and 30 days post hospital discharge
Title
Number of Participants With Score 16 or Greater on CES-D (Center for Epidemiologic Studies Depression Scale)
Description
Number of participants with score 16 or greater on CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
Time Frame
Baseline, Day 2, Day 7, and Day 14 post transplant
Title
CES-D (Center for Epidemiologic Studies Depression Scale)
Description
CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
Time Frame
Baseline, Day 2, 7, 14, 28, and 90
Title
The Positive and Negative Affect Schedule (PANAS)
Description
PANAS is a 20-item self-report measure of positive and negative affect. Each item rated on a 5-point scale of 1 (not at all) to 5 (extremely), each subscale from 1-5, full score from 1-5, with higher score indicating more symptoms. Change in PANAS at Day 30 and Day 90 as compared to baseline.
Time Frame
Baseline, Day 30, Day 90
Title
Change in Brief Symptoms Inventory-18 (BSI-18)
Description
Brief Symptom Inventory-18 (BSI-18) - self-report 18-item instrument. Raw scores on the BSI-18 are converted to t-scores based on gender-specific normative data from non-patient community dwelling U.S. adults. A T-score = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating more symptom.
Time Frame
Baseline and Day 90
Title
Fatigue Line Scale
Description
Simple numeric graphic rating scale, marked on a line numbering 0-100, with higher score indicating more fatigue. Replaces the FACIT fatigue scale for daily fatigue assessment during inpatient procedures.
Time Frame
baseline, day 2, 7, and 14
Title
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF)
Description
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF) is a 30-item short form of the MFSI that measures five dimensions: general, physical, emotional, mental fatigue, and vigor. Each item is rated on a five-point Likert scale from 0 (not at all) to 4 (extremely). The total MFSI-SF score ranges from 0-4, with a higher score indicating a higher fatigue level.
Time Frame
Baseline, Day 30 after Discharge, Day 90 after Discharge
Title
Sleep Latency
Description
Sleep latency measured by actigraph - Sleep latency is the average period of time between bed time and sleep start time
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Sleep Efficiency
Description
Sleep efficiency measured by actigraph - Sleep efficiency is defined as the average percentage of time in bed actually spent sleeping
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Wake Time
Description
Wake time measured by actigraph. Wake time is the average number of minutes the participant spent awake each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Wake Percent
Description
Wake percent measured by actigraph - Wake percent is the average percent of each night spent awake
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Sleep Time
Description
Sleep time measured by actigraph. Sleep time - average number of minutes the participant was asleep each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Sleep Percent
Description
Sleep percent measured by actigraph. Sleep percent is the percent of time spent in bed that the participant is asleep.
Time Frame
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Title
Melatonin
Description
Melatonin level
Time Frame
Baseline and Discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Who will undergo their first autologous HSCT procedure as treatment for multiple myeloma AND: Who are currently 21 years of age or older English language proficient Able to provide informed consent Exclusion Criteria: Under age 21 Previous HSCT procedure (autologous or allogeneic)Pregnancy Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage) Secondary cancer diagnosis within the last 5 years Severe sleep disorders (e.g., Narcolepsy) History of bipolar disorder or manic episodes (which is a contra-indication for light treatment) Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months) Previous use of light therapy to alleviate fatigue or depressive symptoms
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William H. Redd, Ph.D.
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
https://ghr.nlm.nih.gov/condition/multiple-myeloma
Description
Multiple Myeloma
URL
https://medlineplus.gov/fatigue.html
Description
Fatigue
URL
https://rarediseases.info.nih.gov/
Description
Genetic and Rare Diseases Information Center

Learn more about this trial

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue

We'll reach out to this number within 24 hrs